Affymax, Inc. (AFFY) and Takeda Global Research & Development Center, Inc., U.S., announced that the U.S. Food and Drug Administration, or FDA, accepted for review the New Drug Application, or NDA, for peginesatide for the treatment of anemia associated with chronic kidney disease, or CKD, in adult patients on dialysis.
According to Affymax, if approved, peginesatide will be the first once-monthly erythropoiesis stimulating agent available for the treatment of anemia associated with CKD patients on dialysis in the US.
Peginesatide is a synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an ESA.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.